



GLAND PHARMA LIMITED

October 30, 2021

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
25th floor, Dalal Street
Mumbai - 400 001
Scrip Code: 543245

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, 5th floor
Plot no. C-1, Block G, Bandra Kurla Complex Bandra
(East), Mumbai - 400 051
Symbol : GLAND (ISIN : INE068V01023)

Dear Sir/Madam,

Sub: Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') - Details of Related Party Transactions

Ref: Observation on Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') vide mail dated August 20, 2021

With reference to your mail dated August 20, 2021, with regard to the captioned subject and your observation related to provisions pertaining to disclosure under Regulation 23(9) SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015: delay in filing the Disclosure under Regulation 23(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI LODR') - Details of Related Party Transactions by 3 (Three) days.

We hereby state that the disclosure of Related party transactions for Half year ended March 31, 2021 was filed inadvertently in delay with Stock Exchanges, as mentioned above. The Board of Directors of the Company considered the matter and had taken note of the same.

This is for your information and records.

Yours truly,

For Gland Pharma Limited



Sampath Kumar Pallerlamudi
Company Secretary and Compliance Officer